For instance, Cheng H. et al. finds that knockdown of YAP by either shRNA or siRNA improves sensitivity to cisplatin treatment in PC9 lung cancer cells; to radiation treatment in PC9, HCC827 and H157 lung cancer cell lines; and to EGFR tyrosine kinase inhibitor (TKI) erlotinib in EGFR-mutated NSCLC PC9 and HCC827 cell lines [21]. Here, YAP1 is linked to lung carcinoma.